[포스트 IPO]⑤ 지아이이노베이션, LO·마일스톤에 거는 기대감

GI Innovation's reliance on licensing-out (LO) deals and milestone revenues to meet KOSDAQ listing requirements—bypassing the traditional path of drug commercialization—represents a significant model shift in biotech financing. The company's 2.6 trillion KRW in LO achievements and expected H2 2026 milestone inflows demonstrate that partnerships can serve as sustainable revenue sources for regulatory compliance. This approach is noteworthy for the broader biotech sector, offering development-stage companies a viable alternative to the high-risk product commercialization path.